Share
Investors' Chronicle
Professor Russell Napier: The equity index fund is a dangerous product
•
The outbreak of Covid-19 sparked a transformation in monetary policy, according to Professor Russell Napier, with governments now effectively controlling money supply. Combine this with a decoupling between the West and China and Napier thinks investors must brace for a period of prolonged inflation.
In this interview, Napier tells the IC’s Mary McDougall what a new era of financial repression might mean for investors, why he thinks China is not investable and where he thinks the best value is in equity markets. He also explains why he thinks it's time to invest with active fund managers over index funds and what he thinks are the most common mistakes that private investors make.
Napier is a consultant, investor, historian, writer and Honorary Professor at both Heriot-Watt University and The University of Stirling. He’s advised institutions on asset allocation since the mid ‘90s and is chairman of Mid Wynd International Investment Trust. He's written two books: Anatomy of the Bear: Lessons from Wall St’s Four Great Bottoms and The Asian Financial Crisis 1995-98: Birth of the Age of Debt.
He also runs a course in finance called ‘The Practical History of Financial Markets’ and is keeper of The Library of Mistakes, a charitable venture he set up in Edinburgh in 2014.
Time stamps
01:10 Takeaways from the launch of The Library of Mistakes
03:16 Outlook for inflation and money supply
06:05 Diminishing role of central banks
07:40 What indicators investors should look at
08:48 Outlook for equities
10:26 Implications of financial repression
13:48 Role of tax
15:27 Impact of deglobalisation
18:20 Is China investable?
21:10 Companies that benefit from deglobalisation
23:40 Index funds vs active managers
28:28 Categorising by country vs sector
31:38 Suggestions for novice investors
33:18 Research of Hendrik Bessembinder
34:45 Infrastructure and property
38:29 Re-equitisation
41:42 Problems with the search for yield
44:20 Biggest personal mistake
46:00 Most common mistakes made by private investors
Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities.
Investors' Chronicle is a service by the Financial Times.
More episodes
View all episodes
Back to basics: How to build a portfolio
28:04|Figuring out which funds to buy is overwhelming for even the most experienced investors – but as a beginner, it’s important to understand your options so you can make the right decisions. Funds editor Val Cipriani is in the studio with personal finance editor Holly McKechnie to break down the process. First, the duo explains what a fund is, the three main types, and why they are a good option to kick-start your investment journey. Val then dives into the difference between stocks and bonds, while also helping you to understand risk tolerance and how to figure out what kind of investor you are or want to be.Before rounding off, Val gets into the nitty-gritty of portfolio-building best practices. From keeping it manageable to controlling your costs, Val and Holly have you covered. If you want to get started, you can check out our Top 50 funds here.Timestamps00:00 Intro00:45 Why a fund is a good option for beginner investors04:32 The different types of funds13:30 How to build a portfolio and decide your asset allocation17:36 Understanding active fundsListen to episodes of Women & Wealth by clicking here or on ACast, Apple, Spotify or YouTube.If you have any questions you’d like the duo to answer, email val.cipriani@ft.com or holly.mckechnie@ft.com
Semiconductor stocks, our Top 50 Funds and Mortgage Advice Bureau: Companies and Markets Show
37:07|Even as uncertainty reins in the markets, 2026 has been another bumper year for returns. But, as ever, that does hide plenty of dispersion below the surface; with that in mind, this week’s show looks at two stocks at opposite ends of the scale.One is up over 800 per cent in the year to date – that’s semiconductor manufacturer IQE, which reported interim results on Monday. Michael Fahy is in the studio to dive into the details and ask whether its run can continue.At the other end of the spectrum is Mortgage Advice Bureau, which fell 20 per cent on Wednesday after lowering full-year guidance. Julian Hofmann asks whether there’s any light at the end of the tunnel after it departed from Aim, and will also run the rule over the thus-far better-performing Property Franchise Group.In between, we turn to our Top 50 Funds of 2026. Val Cipriani and her expert panel have compiled our annual rundown of 50 active funds we think may be suitable for a range of investors. Val talks through our picks.Timestamps: 00:00 Intro01.14 IQE14:19 Top 50 Funds26:17 Mortgage Advice BureauListen to more podcasts from Investors’ Chronicle on Apple, Spotify and YouTube
Our favourite ETFs, toxic stocks to avoid and industrials: Companies and Markets show
38:38|This week’s show begins with a look at Meta after the social media giant had to fork out $18bn following accusations that its products are deliberately addictive for younger people. Valeria Martinez is in the studio to discuss whether big tech and other sectors are now the new ‘sin stocks’ and whether the companies which are so irresistible to consumers are toxic for investors. We then discuss our annual Top 50 ETFs best-buy list, released earlier this summer. Val Cipriani talks us through how it was compiled, some of the changes, and what investors should consider when buying tracker funds.Finally, we look at building materials supplier Grafton, which released half-year results on Thursday morning. Mark Robinson weighs up whether its UK struggles are being offset by better business in the rest of Europe and its home market of Ireland, and what this means for the investment case.Timestamps:00:00 Intro01:09 Top 50 ETFs12:34 A new age of 'Sin stocks'27:10 Grafton's resultsListen to more podcasts from Investors’ Chronicle on Apple, Spotify and YouTube
Protecting your pension, UK industrials and Nvidia: Companies and Markets Show
28:34|First, we cast our ears to British industrial stocks and ask whether they are being picked off too cheaply. Michael Fahy dives into why manufacturers are significantly more undervalued than their US counterparts and discusses the sector’s acquisitions in recent years.We then turn to what is arguably our most important savings pot: the pension. You may have saved diligently and kept a close eye on your investments, but unexpected problems can still arise. From a later-life divorce or a stock market slump, plenty can throw retirement into jeopardy. But fret not, Holly McKechnie is in the studio to talk through the most common threats – and how to avoid them. Finally, we look at Nvidia and its keenly anticipated earnings update. To investors’ joy, it delivered on all fronts and revenue at the world’s largest company more than doubled, smashing Wall Street’s expectations. Arthur Sants explains the latest figures and its new circular financing strategy, which is raising a lot of eyebrows (more on that here).Timestamps00:00 Intro03:32 Are UK industrials being picked off too cheaply?19:95 Common risks to your pension – and how to avoid them20:36 Nvidia's promising figures and new financing strategyListen to more podcasts from Investors’ Chronicle on Apple, Spotify and YouTube
How to invest under Andy Burnham: Lee and the IC
44:44|After a summer hiatus, Alex Newman and Lord Lee are back in the studio, and the duo have a lot to catch up on. The UK has seen a change of prime minister, record-breaking heat and plenty of action in stock markets.First, the pair turn to Britain’s new government. While Andy Burnham and John Healey have revealed very little about their fiscal plans, Lord Lee gives his thoughts, including how to encourage the country’s sleepy retail investor base. The episode then moves to listener questions, John’s approach to stockpicking and the latest buys, sells and changes in his own portfolio. Highlights include Primary Health Properties’ lofty yield and why he believes investing is an “art rather than a science”.Timestamps00:00 Intro01:08 Lord Lee's thoughts on Burnham's Britain10:18 A look into John's portfolio: Buys and sells21:09 Jet2, PZ Cussons, Christie Group and more33:26 Goodwin, income stocks and takeover opportunitiesLet us know your thoughts, or if you have any questions or any suggestions for future guests, by emailing alex.newman@ft.comListen to more podcasts from Investors’ Chronicle by clicking here or heading to Apple, Spotify and YouTube
JD Sports, Pershing Square’s overhaul and Oxford Nanopore:Companies and Markets Show
28:04|Up first this week is self-labelled ‘King of Trainers’ JD Sports, whose shares took a 15 per cent tumble on Thursday morning. The FTSE 100 retailer has blamed much of the slump on delayed back-to-school spending and a rising cost of living. Erin Withey explains what’s going on.Next we turn to what has become a trend of the past few months: star fund managers overhauling portfolios. Bill Ackman of Pershing Square has joined the party in trying to stop disappointing returns, but when your portfolio only has around 12 stocks, and you change 11 of them, it’s going to have some significant repercussions. Val Cipriani is in the studio to discuss whether the shake-up is for the better or whether investors should be worried. Finally, we look at Oxford Nanopore; initial excitement after its IPO has waned, and the testing company has struggled as its biggest segment, its research arm, has lagged. Julian Hofmann dives into its management’s plans to switch up its strategy and what this means for shareholders.Timestamps: 00:00 Intro3:59 JD Sports10:57 Pershing Square20:08 Oxford NanoporeListen to more podcasts from Investors’ Chronicle on Apple, Spotify and YouTube
Legal & General, infrastructure stocks and GSK: Companies and Markets Show
26:16|After an avalanche of earnings updates, we turn to our annual Income Majors special report and dive into two prominent FTSE 100 dividend stocks. First up is insurer Legal & General; pressure has been mounting on the company as it grapples with a more competitive pensions market. Christopher Akers explains the CEO’s buyback plan, its yield and what it means for investors.We then move to GSK, once known as GlaxoSmithKline, which faces a tricky balancing act between dividends and developing new drugs. The pharma giant has been spending heavily on R&D – a staggering £18bn this year alone to build its oncology pipeline. Julian Hofmann has the details.Finally, we cast our ears to Hill & Smith’s growth across the pond. The steel products company now generates two-thirds of its revenue from the US and has even switched its currency from sterling to dollars. Michael Fahy discusses what’s going on at the growing business.Timestamps: 00:00 Intro03:22 Legal & General10:42 GSK18:57 Hill & Smith Listen to more podcasts from Investors’ Chronicle on Apple, Spotify and YouTube
How to defeat the gender wealth gap
27:44|Women, on average, earn less than men, have less saved in a pension and have to take more time off from work to care for others. But while society is rigged to burden women with heavier loads, Gina Miller has made it her mission to change this and close the gender wealth gap. Gina is an activist, entrepreneur and the founder of MoneyShe, an investment platform focused on women’s finances. Gina, who became widely known for her anti-Brexit campaign and has spent decades working in the City, sits down with funds editor Val Cipriani to discuss the barriers blocking women from investing, the inherent misogyny in finance and practical steps to build a portfolio.She also discusses the financial consequences of having cancer and her experience with economic abuse.Timestamps00:00 Introduction02:41 Understanding the gender wealth gap06:09 Why women invest less than men10:41 Practical tips for getting started15:12 Misogyny in finance and campaigning for change20:02 The financial impact of cancer23:12 Economic abuse and financial independence26:24 MoneyShe and Gina’s current campaigning workWomen and Wealth is the monthly podcast series from Investors’ Chronicle. You can listen to and watch the episodes alongside our other podcasts on Acast, Apple, Spotify or YouTube.If you have any questions you’d like Val to answer in the podcast, email val.cipriani@ft.com
The AI jobs crunch, medical stocks and AstraZeneca: Companies and Markets Show
37:40|M&A activity remains rampant, and this week we start with a tie-up that would rank among the biggest deals of all time: AstraZeneca and US rival Bristol Myers Squibb. Julian Hofmann discusses the merits of the mooted $400bn deal, the drawbacks and why investors’ response to the rumour has been bleak. We then turn to what could be the greatest disrupter humans have seen for decades: the rise of AI and what it means for the jobs market. As speculation runs rampant as to how many roles could be lost, Hugh Moorhead is in the studio to curb some of those concerns. Hugh explains what’s actually going on, which companies might stand to benefit, which might not, and how investors should respond.Finally, Mark Robinson puts medical device maker Smith & Nephew under the microscope after its half-year figures suggest its long-awaited rebound hasn’t quite arrived. But with an activist lurking on the shareholder register, could better times be on the way?Timestamps00:00 Introduction1:20 AstraZeneca15:43 AI's impact on the jobs market and what this means for investors30:23 Smith & NephewListen to more podcasts from Investors’ Chronicle on Apple, Spotify and YouTube